Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cabotegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 17/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.85 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabotegravir SCHEMBL22584741 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL93097 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL18253200 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL18881147 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL81491 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL82803 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL29374458 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL10002356 | 1.00 | SLC22A2 (0.85) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL19987969 | 0.99 | SLC22A2 (0.83) | SLC22A2CYP3A4TMEM97ABCG2 | |
| Cabotegravir SCHEMBL82533 | 0.99 | SLC22A2 (0.83) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675843-A1 | PERYLENEBISIMIDE - POLYESTER BLEND | Council of Scientific & Industrial Research (IN) | 2013-12-25 | — | — | EP | claimed |
| WO-2012111026-A1 | PERYLENEBISIMIDE - POLYESTER BLEND | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860) (IN) | 2012-08-23 | — | — | WO | claimed |
| EP-1874117-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SmithKline Beecham Corporation (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006116764-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-02 | — | — | WO | claimed |
| US-20250296988-A1 | COMBINATION THERAPY | VIIV HEALTHCARE COMPANY | 2025-09-25 | — | — | US | disclosed |
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-3870174-B1 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | UNIV NEBRASKA (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2023175386-A2 | PROCESSES FOR PREPARATION OF CABOTEGRAVIR OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2023-09-21 | — | — | WO | disclosed |
| EP-4234561-A2 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Board of Regents of the University of Nebraska (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234560-A2 | ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF | Board of Regents of the University of Nebraska (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230120910-A1 | REGIMENS FOR TREATING HIV INFECTIONS AND AIDS | VIIV HEALTHCARE COMPANY | 2023-04-20 | — | — | US | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2015177537-A1 | PROCESS FOR PREPARING POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES AND INTERMEDIATES THEREOF | CIPLA LIMITED (IN) | 2015-11-26 | — | — | WO | disclosed |
| US-20140357643-A1 | Derivatives of Betulin | GLAXOSMITHKLINE LLC | 2014-12-04 | — | — | US | disclosed |
| WO-2012037320-A3 | PHARMACEUTICAL COMPOSITIONS | VIIV HEALTHCARE COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| CN-103547266-A | Pharmaceutical compositions | GLAXOSMITHKLINE LLC | 2014-01-29 | — | — | CN | disclosed |
| EP-2675843-A1 | PERYLENEBISIMIDE - POLYESTER BLEND | Council of Scientific & Industrial Research (IN) | 2013-12-25 | — | — | EP | disclosed |
| EP-2616076-A2 | PHARMACEUTICAL COMPOSITIONS | VIIV Healthcare Company (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012111026-A1 | PERYLENEBISIMIDE - POLYESTER BLEND | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860) (IN) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012037320-A2 | PHARMACEUTICAL COMPOSITIONS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279238-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, CDKN1A, POLL | SLC22A2 4476/4885CYP3A4 527/4885TMEM97 4291/4885 |
| US-20140357643-A1 | Derivatives of Betulin | BET1, TMPO, PGGT1B | SLC22A2 2022/4885CYP3A4 1056/4885TMEM97 3735/4885 |
| US-20230120910-A1 | REGIMENS FOR TREATING HIV INFECTIONS AND AIDS | SAMHD1, CCR5, SLC6A12 | SLC22A2 1479/4885CYP3A4 145/4885TMEM97 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.